中药对肿瘤组织血管生成的影响

恶性肿瘤的无限制侵袭性生长及其转移依赖于血管生成（angiogenesis)抑制血管生成是不同于常规的肿瘤治疗新策略，肿瘤血管生成的过程是个多步骤过程，目前已进入临床的肿瘤血管生成抑制剂有数十种，许多有抗肿瘤活性的中药的有效成分，如：人参皂苷Rg^3、鲨鱼软骨生成抑因子（SCAIF）等可抑制肿瘤血管生成。     

视网膜母细胞瘤基因产物磷酸化水平与细胞生长状态的关系

随着无血清培养细胞时间的延长，红胞合成Ｒｂ蛋白量和磷酸化水平逐渐降低，当细胞生长停止时，Ｒｂ蛋白处于低磷外化状态．正丁酸钠可诱导ＨＬ６０终端分化为单核－巨噬细胞；视黄酸、二甲基亚砜使ＨＬ６０分化为粒细胞．尽管分化途径不同．但是终端分化的细胞都只能合成低磷酸化的Ｒｂ蛋白．结果表明当细胞处于生长停滞状态，细胞都只能合成低磷酸化的Ｒｂ蛋白．     

恶性肿瘤患者与健康人血清Cu、Zn、Ca、Mg、Se含量及Cu／Zn比值的对比分析

用ＩＣＰ－ＡＥＳ法测定了４４例恶性肿瘤患者和３３例健康人血清Ｃｕ、Ｚｎ、Ｃａ、Ｍｇ、Ｓｅ含量．结果显示：恶性肿瘤组血清Ｃａ、Ｓｅ含量低于健康组，血清Ｃｕ含量高于健康组，两组相比较，均有非常显著差异（Ｐ＜０．０１）．提示上述元素可能与恶性肿瘤的发生、发展有一定关系．     

蝙蝠葛碱增强博莱霉素A5对肿瘤细胞的毒性

应用增殖抑制方法发现,无生长抑制作用的0.5mg ·L~(-1)的蝙蝠葛碱(Dau)使博莱霉素A_5单独对小鼠肉瘤S-180V细胞作用的I_(C50)值从2.1mg·L~(-1)降低到1.3mg·L~(-1),无抑制作用的1 mg·L~(-1) Dau使博莱霉素A_5单独对人喉癌HEP2细胞作用的I_(C50) 值从0.33 mg·L~(-1)降低到0.1 mg·L~(-1).克隆形成法证明:无细胞毒性的10 mg·L~(-1)的Dau明显增强博莱霉素A_5对HEP2细胞毒性.TFP法证实,有一定生长抑制作用的Dau对HEP2细胞内活化钙调素有影响.结果表明:蝙蝠葛碱有一定的增强博莱霉素A_5对肿瘤细胞的毒性.     

槲皮素抗癌作用的分子机制

槲皮素是已知最强的抗癌剂之一。从分子水平的角度阐述了其抗癌作用机制的研究进展。其中包括结合雌激素受体，下调变异的P53蛋白，阻滞细胞周期，抑制酪氨酸激酶，促进凋亡，阻遏热休克蛋白和抑制Ras的表达等等。随着其分子机制的深入研究，可以为临床治疗提供更好的理论依据。     

复方癌立消抗肿瘤活性的研究

癌立消为验方，取长白山新鲜中药配制而成，实验用NIH小鼠移植Ehrlieh癌造成实体瘤模型。随机分四组。对照组不给药，阳性对照组给环磷酰胺剂量100mg／kg、癌立消剂量为成人剂量5倍(2．6g／kg)和10倍(5．2g／kg)两组。结果表明：癌立消有明显的抑瘤作用。5倍成人剂量组抑瘤率为43．9％-50．4％，10倍成人剂量组为53．3％-56．3％，而且有统计学意义。     

Inhibitory effect of the adenovirus type 5 E1A protein expressed in the yeast system

The human adenovirus type 5 E1A, a tumor- suppressor gene[1], codes for two major related proteins of 243 amino acids (12S) and 289 amino acids (13S) by al-ternative splicing in two exons[2]. Studies have been shown that E1A can regulate expression of many genes and cell cycle[3]. Both in vitro and in vivo experiments indicated that E1A could induce tumor cells differentia-tion, convert tumor cells into an epithelial phenotype, in-hibit tumor cell growth and metastasis and strongly en-ha…     

The neurotrophic receptor TrkB: a drug target in anti-cancer therapy?

Increasing evidence implies altered signaling through the neurotrophic receptor tyrosine kinase TrkB in promoting tumor formation and metastasis. TrkB, sometimes in conjunction with its primary ligand BDNF, is often overexpressed in a variety of human cancers, ranging from neuroblastomas to pancreatic ductal adenocarcinomas, in which it may allow tumor expansion and contribute to resistance to anti-tumor agents. In vitro, TrkB acts as a potent suppressor of anoikis (detachment-induced apoptosis), which is associated with the acquisition of an aggressive tumorigenic and metastatic phenotype in vivo. In view of its predicted contribution to tumorigenicity and metastasis in humans, TrkB corresponds to a potential drug target, and preclinical models have already been established. The encouraging results of pharmacological Trk inhibitors in tumor xenograft models suggest that TrkB inhibition may represent a promising novel anti-tumor therapeutic strategy. This hypothesis is currently being evaluated in clinical trials. Here, we will discuss the latest developments on TrkB in these contexts as well as highlight some critical questions that remain to be addressed for evaluating TrkB as a therapeutic target in cancer. Received 12 October 2005; received after revision 19 December 2005; accepted 11 January 2006     

HAb18G/CD147-mediated calcium mobilization and hepatoma metastasis require both C-terminal and N-terminal domains

HAb18G/CD147 is a heavily glycosylated protein containing two immunoglobulin superfamily domains. Our previous studies have indicated that overexpression of HAb18G/CD147 enhances metastatic potentials in human hepatoma cells by disrupting the regulation of store-operated Ca²⁺ entry by nitric oxide (NO)/cGMP. In the present study, we investigated the structure-function of HAb18G/CD147 by transfecting truncated HAb18G/CD147 fragments into human 7721 hepatoma cells. The inhibitory effect of HAb18G/CD147 on 8-bromo-cGMP-regulated thapsigargin-induced Ca²⁺ entry was reversed by the expression of either C or N terminus truncated HAb18G/CD147 in T7721C and T7721N cells, respectively. The potential effect of HAb18G/CD147 on metastatic potentials, both adhesion and invasion capacities, of hepatoma cells was abolished in T7721C cells, but not affected in T7721N cells. Release and activation of matrix metalloproteinases (MMPs), MMP-2 and MMP-9, were found to be enhanced by the expression of HAb18G/CD147, and this effect was abolished by both truncations. Thapsigargin significantly enhanced release and activation of MMPs (MMP-2 and MMP-9) in non-transfected 7721 cells, and this effect was negatively regulated by SNAP. However, no effects of thapsigargin or SNAP were observed in T7721 cells, and expression of HAb18G/CD147 enhanced secretion and activation of MMPs at a stable and high level. Taken together, these results suggest that both ectodomain and intracellular domains of HAb18G/CD147 are required to mediate the effect of HAb18G/CD147 on the secretion and activation of MMPs and metastasis-related processes in human hepatoma cells by disrupting the regulation of NO/cGMP-sensitive intracellular Ca²⁺ mobilization although each domain may play different roles.Received 1 April 2004; received after revision 15 June 2004; accepted 22 June 2004     

一个与人类待定肿瘤抑制基因同源的水稻基因的分离

从水稻基因文库中筛选到一个与人类待定肿瘤抑制基因QM同源的基因,命名为OSQM2．该基因片断长为3．1kb,编码一个具有184个氨基酸的高度碱性的蛋白质,与其他已知QM基因相比,该基因具有一个非常特殊的启动子,包含许多在植物中已发现的与抗逆有关的顺式作用因子,如：“G盒”,“DRE盒”,“MYC盒”等,故而该基因有可能是一个新的受环境胁迫因子诱导的基因,Southern杂交表明它以单拷贝形式存在于基因组中。